Develops a digital PCR assay for detecting early lung cancer, suggesting potential for improved clinical outcomes.
Early detection and treatment monitoring are crucial to improve clinical outcomes in lung cancer. Circulating tumor DNA (ctDNA) has rapidly emerged as a promising non-invasive tool, yet clinically validated biomarkers with high specificity and sensitivity remain limited. This study aimed to develop and validate a digital PCR-based liquid biopsy assay using novel DNA methylation biomarkers for lung cancer detection and disease monitoring.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: